FDA Grants Orphan Drug Designation to Padeliporfin VTP for Pancreatic Cancer

The FDA has granted orphan drug designation to padeliporfin vascular targeted photodynamic therapy for use as a potential therapeutic option in patients with locally advanced pancreatic cancer.

Related Keywords

United States ,Israel ,Israeli ,Barak Palatchi ,European Union ,Impact Biotech ,Pact Biotech ,Solid Tumors ,Pancreatic Cancer ,Fda ,Padeliporfin Vtp ,Orphan Drug Designation ,Padeliporfin Vascular Targeted Photodynamic Therapy ,